{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:57:40Z","timestamp":1789012660394,"version":"build-2803163510"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01694","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T06:14:36Z","timestamp":1596176076000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation"],"prefix":"10.3389","volume":"11","author":[{"given":"Manar S.","family":"Shafat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedika","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl S.","family":"Peggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Roddie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1172\/JCI90599","article-title":"Immunotherapy for transplantation-associated viral infections","volume":"127","author":"Roddie","year":"2017","journal-title":"J Clin Invest."},{"key":"B2","first-page":"60","article-title":"Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and epstein-Barr virus infections","volume":"10","author":"Razonable","year":"2003","journal-title":"Herpes J IHMF."},{"key":"B3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1084\/jem.20050882","article-title":"Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects","volume":"202","author":"Sylwester","year":"2005","journal-title":"J Exp Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"7569","DOI":"10.1128\/JVI.70.11.7569-7579.1996","article-title":"The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL","volume":"70","author":"Wills","year":"1996","journal-title":"J Virol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.3389\/fimmu.2017.01591","article-title":"Comprehensive analysis of cytomegalovirus pp65 antigen-specific CD8+ T cell responses according to human leukocyte antigen class I allotypes and intraindividual dominance","volume":"8","author":"Hyun","year":"2017","journal-title":"Front Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1086\/655472","article-title":"Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature","volume":"202","author":"van de Berg","year":"2010","journal-title":"J Infect Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1056\/NEJM198906293202605","article-title":"Severe herpesvirus infections in an adolescent without natural killer cells","volume":"320","author":"Biron","year":"1989","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1743-422X-6-4","article-title":"Feeling manipulated: cytomegalovirus immune manipulation","volume":"6","author":"Miller-Kittrell","year":"2009","journal-title":"Virol J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2217\/fvl.12.8","article-title":"The immune response to human CMV","volume":"7","author":"La Ros","year":"2012","journal-title":"Future Virol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1399-3062.2010.00504.x","article-title":"Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy","volume":"12","author":"George","year":"2010","journal-title":"Transpl Infect Dis."},{"key":"B11","first-page":"1207","article-title":"Infection after pediatric heart transplantation: results of a multiinstitutional study. The pediatric heart transplant study group","volume":"16","author":"Schowengerdt","year":"1997","journal-title":"J Heart Lung Transplant."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1182\/blood.V99.6.1978","article-title":"Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study","volume":"99","author":"Junghanss","year":"2002","journal-title":"Blood."},{"key":"B14","first-page":"1075","article-title":"Severe infections after allogeneic peripheral blood stem cell transplantation: a matched-pair comparison of unmanipulated and CD34+ cell-selected transplantation","volume":"86","author":"Martino","year":"2001","journal-title":"Haematologica."},{"key":"B15","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/cid\/cix325","article-title":"Dasatinib use and risk of cytomegalovirus reactivation after allogeneic hematopoietic-cell transplantation","volume":"65","author":"Prestes","year":"2017","journal-title":"Clin Infect Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s40265-018-0943-1","article-title":"New developments in the management of cytomegalovirus infection after transplantation","volume":"78","author":"Meesing","year":"2018","journal-title":"Drugs."},{"key":"B17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/2279-042X.176554","article-title":"The risk factors for cytomegalovirus reactivation following stem cell transplantation","volume":"5","author":"Valadkhani","year":"2016","journal-title":"J Res Pharm Pract."},{"key":"B18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1399-3062.2008.00344.x","article-title":"Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation","volume":"11","author":"Cummins","year":"2009","journal-title":"Transpl Infect Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.bbmt.2006.12.454","article-title":"Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients","volume":"13","author":"Matsumura","year":"2007","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant."},{"key":"B20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/jmv.21727","article-title":"Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital","volume":"82","author":"Fleming","year":"2010","journal-title":"J Med Virol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1182\/blood.V97.4.867","article-title":"Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes","volume":"97","author":"Nichols","year":"2001","journal-title":"Blood."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1182\/blood.V86.7.2815.bloodjournal8672815","article-title":"Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation","volume":"86","author":"Einsele","year":"1995","journal-title":"Blood."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant."},{"key":"B24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1083-8791(03)00287-8","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies","volume":"9","author":"Boeckh","year":"2003","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1056\/NEJM199112053252303","article-title":"Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation","volume":"325","author":"Goodrich","year":"1991","journal-title":"N Engl J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.7326\/0003-4819-118-3-199302010-00003","article-title":"Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant","volume":"118","author":"Goodrich","year":"1993","journal-title":"Ann Intern Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1182\/blood-2016-06-688432","article-title":"How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients","volume":"128","author":"El Chaer","year":"2016","journal-title":"Blood."},{"key":"B28","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.bbmt.2010.07.026","article-title":"An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients","volume":"17","author":"Pollack","year":"2011","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1182\/blood.V90.6.2502.2502_2502_2508","article-title":"Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome","volume":"90","author":"Salzberger","year":"1997","journal-title":"Blood."},{"key":"B30","doi-asserted-by":"publisher","first-page":"18S","DOI":"10.1016\/0002-9343(91)90406-N","article-title":"Antiretroviral therapy and immunomodulators in patients with AIDS","volume":"90","author":"Groopman","year":"1991","journal-title":"Am J Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/sj.bmt.1702450","article-title":"Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study","volume":"26","author":"Bregante","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"B32","doi-asserted-by":"publisher","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study","volume":"111","author":"Winston","year":"2008","journal-title":"Blood."},{"key":"B33","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.bbmt.2020.01.027","article-title":"Letermovir for secondary prophylaxis of CMV infection and disease after allogeneic hematopoietic cell transplantation: results from the French compassionate program","volume":"6","author":"Robin","year":"2020","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant."},{"key":"B36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11908-019-0699-0","article-title":"CMV prevention and treatment in transplantation: what's new in 2019","volume":"21","author":"Stern","year":"2019","journal-title":"Curr Infect Dis Rep."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1111\/ajt.15764","article-title":"Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation","volume":"20","author":"Marty","year":"2019","journal-title":"Am J Transplant."},{"key":"B38","doi-asserted-by":"publisher","first-page":"104549","DOI":"10.1016\/j.antiviral.2019.104549","article-title":"In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","volume":"169","author":"Komatsu","year":"2019","journal-title":"Antiviral Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.bbmt.2014.11.002","article-title":"Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies","volume":"21","author":"Boeckh","year":"2015","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N Engl J Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","article-title":"Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy","volume":"99","author":"Einsele","year":"2002","journal-title":"Blood."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0140-6736(03)14634-X","article-title":"Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines","volume":"362","author":"Peggs","year":"2003","journal-title":"Lancet Lond Engl."},{"key":"B43","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1182\/blood-2005-05-1775","article-title":"Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation","volume":"106","author":"Perruccio","year":"2005","journal-title":"Blood."},{"key":"B44","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/CJI.0b013e31824300a2","article-title":"Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections","volume":"35","author":"Bao","year":"2012","journal-title":"J Immunother."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.bbmt.2015.05.015","article-title":"Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia","volume":"21","author":"Koehne","year":"2015","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/nm1475","article-title":"Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals","volume":"12","author":"Leen","year":"2006","journal-title":"Nat Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1182\/blood-2008-06-161695","article-title":"Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation","volume":"112","author":"Micklethwaite","year":"2008","journal-title":"Blood."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol Ther J Am Soc Gene Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.it.2011.11.005","article-title":"Memory T cell inflation: understanding cause and effect","volume":"33","author":"O'Hara","year":"2012","journal-title":"Trends Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1038\/leu.2017.16","article-title":"Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT","volume":"31","author":"Neuenhahn","year":"2017","journal-title":"Leukemia."},{"key":"B52","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","article-title":"Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation","volume":"116","author":"Feuchtinger","year":"2010","journal-title":"Blood."},{"key":"B53","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/cid\/ciq042","article-title":"Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation","volume":"52","author":"Peggs","year":"2011","journal-title":"Clin Infect Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/CJI.0b013e31826e35f6","article-title":"Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with in vitro-generated CMV pp65-specific CD8+ T-cell lines","volume":"35","author":"Meij","year":"2012","journal-title":"J Immunother."},{"key":"B55","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1182\/bloodadvances.2017010223","article-title":"Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells","volume":"1","author":"Withers","year":"2017","journal-title":"Blood Adv."},{"key":"B57","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, epstein-barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/CJI.0000000000000197","article-title":"Early experience with CliniMACS prodigy CCS (IFN-gamma) system in selection of virus-specific T cells from third-party donors for pediatric patients with severe viral infections after hematopoietic stem cell transplantation","volume":"41","author":"K\u00e1llay","year":"2018","journal-title":"J Immunother."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1182\/bloodadvances.2019000201","article-title":"Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients","volume":"3","author":"Abraham","year":"2019","journal-title":"Blood Adv."},{"key":"B60","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol Oncol Clin North Am."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/eji.201343946","article-title":"Viral inoculum dose impacts memory T-cell inflation","volume":"44","author":"Redeker","year":"2014","journal-title":"Eur J Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1182\/blood.V78.5.1373.bloodjournal7851373","article-title":"Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease","volume":"78","author":"Reusser","year":"1991","journal-title":"Blood."},{"key":"B63","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2217\/imt.14.99","article-title":"Cytomegalovirus-specific T-cell therapies: current status and future prospects","volume":"7","author":"Nicholson","year":"2015","journal-title":"Immunotherapy."},{"key":"B64","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1086\/648422","article-title":"Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation","volume":"49","author":"Peggs","year":"2009","journal-title":"Clin Infect Dis."},{"key":"B66","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.bbmt.2007.02.004","article-title":"Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Micklethwaite","year":"2007","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant."},{"key":"B67","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2217\/imt.15.110","article-title":"Cytomegalovirus and immunotherapy: opportunistic pathogen, novel target for cancer and a promising vaccine vector","volume":"8","author":"Quinn","year":"2016","journal-title":"Immunotherapy."},{"key":"B68","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12967-014-0317-8","article-title":"CMV-specific T cell isolation from G-CSF mobilized peripheral blood: depletion of myeloid progenitors eliminates non-specific binding of MHC-multimers","volume":"12","author":"Beloki","year":"2014","journal-title":"J Transl Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1084\/jem.20040613","article-title":"Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers","volume":"202","author":"Cobbold","year":"2005","journal-title":"J Exp Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1537-2995.2010.02940.x","article-title":"Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation","volume":"51","author":"Schmitt","year":"2011","journal-title":"Transfusion."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1182\/blood-2010-10-310599","article-title":"Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice","volume":"117","author":"Wang","year":"2011","journal-title":"Blood."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood."},{"key":"B73","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood."},{"key":"B74","doi-asserted-by":"publisher","first-page":"8243","DOI":"10.4049\/jimmunol.179.12.8243","article-title":"CD4 T cells are required for CD8 T cell survival during both primary and memory recall responses","volume":"179","author":"Novy","year":"2007","journal-title":"J Immunol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.bbmt.2017.10.004","article-title":"Virus-specific T cells: broadening applicability","volume":"24","author":"Barrett","year":"2018","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/bmt.2016.17","article-title":"Virus-specific T-cell banks for \u201coff the shelf\u201d adoptive therapy of refractory infections","volume":"51","author":"O'Reilly","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3389\/fimmu.2017.01272","article-title":"Virus-specific T cells for the immunocompromised patient","volume":"8","author":"Houghtelin","year":"2017","journal-title":"Front Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1182\/blood-2009-03-213256","article-title":"Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes","volume":"114","author":"Hanley","year":"2009","journal-title":"Blood."},{"key":"B80","doi-asserted-by":"publisher","first-page":"7934","DOI":"10.1073\/pnas.0500357102","article-title":"A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection","volume":"102","author":"Morris","year":"2005","journal-title":"Proc Natl Acad Sci USA."},{"key":"B81","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1182\/blood-2005-01-0146","article-title":"Elimination of human leukemia cells in NOD\/SCID mice by WT1-TCR gene-transduced human T cells","volume":"106","author":"Xue","year":"2005","journal-title":"Blood."},{"key":"B82","doi-asserted-by":"publisher","first-page":"6819","DOI":"10.4049\/jimmunol.0902233","article-title":"CMV-specific TCR-transgenic T cells for immunotherapy","volume":"183","author":"Schub","year":"2009","journal-title":"J Immunol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2010-12-326736","article-title":"Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen","volume":"118","author":"Thomas","year":"2011","journal-title":"Blood."},{"key":"B84","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1038\/s41467-019-12441-w","article-title":"Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function","volume":"10","author":"Thomas","year":"2019","journal-title":"Nat Commun."},{"key":"B85","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1182\/blood-2009-07-230482","article-title":"Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)","volume":"114","author":"De Angelis","year":"2009","journal-title":"Blood."},{"key":"B86","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.1182\/blood-2009-07-228387","article-title":"Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease","volume":"114","author":"Brewin","year":"2009","journal-title":"Blood."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1182\/blood-2015-08-664755","article-title":"TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells","volume":"126","author":"Menger","year":"2015","journal-title":"Blood."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/bmt.2015.135","article-title":"Generation of memory T cells for adoptive transfer using clinical-grade anti-CD62L magnetic beads","volume":"50","author":"Verfuerth","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1172\/JCI81229","article-title":"Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts","volume":"125","author":"Bleakley","year":"2015","journal-title":"J Clin Invest."},{"key":"B90","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.bbmt.2014.01.032","article-title":"Engineering human peripheral blood stem cell grafts that are depleted of na\u00efve T cells and retain functional pathogen-specific memory T cells","volume":"20","author":"Bleakley","year":"2014","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant."},{"key":"B91","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1182\/blood-2010-06-289991","article-title":"Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects","volume":"116","author":"Melenhorst","year":"2010","journal-title":"Blood."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e95103","DOI":"10.1172\/jci.insight.95103","article-title":"Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy","volume":"2","author":"Klebanoff","year":"2017","journal-title":"JCI Insight."},{"key":"B94","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08155","article-title":"mTOR regulates memory CD8 T-cell differentiation","volume":"460","author":"Araki","year":"2009","journal-title":"Nature."},{"key":"B95","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nm.1982","article-title":"Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells","volume":"15","author":"Gattinoni","year":"2009","journal-title":"Nat Med."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01694\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T06:14:42Z","timestamp":1596176082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01694\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":95,"alternative-id":["10.3389\/fimmu.2020.01694"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01694","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,31]]},"article-number":"1694"}}